Novel Technologies to Detect Minimal Residual Disease
نویسندگان
چکیده
منابع مشابه
Novel Immunotherapy to Eliminate Minimal Residual Disease in AML Patients
Even with the most sophisticated chemotherapy regimens, the majority of patients with acute myeloid leukemia will eventually experience a relapse and die from their disease. New treatments are needed to prevent relapse of disease in these patients. Immunotherapy using the host immune system to combat leukemia represents an exciting and potentially efficacious addition to standard chemotherapy f...
متن کاملMinimal residual disease in melanoma.
A number of specific genes encoding for melanosomal proteins are selectively expressed in melanocytes and melanomas. For detection of circulating melanoma cells, the expression of the tyrosinase gene is most widely used. Several cohorts of melanoma patients from single institutions have been analyzed by various research groups for the presence of circulating melanoma cells in all stages of dise...
متن کاملA Business Model to Detect Disease Outbreaks
Introduction: Every year several disease outbreaks, such as influenza-like illnesses (ILI) and other contagious illnesses, impose various costs to public and non-government agencies. Most of these expenses are due to not being ready to handle such disease outbreaks. An appropriate preparation will reduce the expenses. A system that is able to recognize these outbreaks can earn ...
متن کاملExploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
PURPOSE Minimal residual disease (MRD) presents a significant hurdle to curing metastatic neuroblastoma. Biological therapies directed against MRD can improve outcome. Evaluating treatment efficacy requires MRD measurement, which serves as surrogate endpoint. Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD mark...
متن کاملMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many adult ALL patients. MRD diagnostics has proven to be the strongest prognostic factor, allowing for risk group assignment into different treatment arms, ranging from significant treatment reduction to mild or strong int...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2016
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v128.22.sci-31.sci-31